DKNG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DKNG is not a strong buy right now for a Beginner long-term investor, even with $50,000-$100,000 available. The stock has decent analyst support and some positive business momentum, but the current technical setup is weak, insider selling is elevated, and there is no strong proprietary buy signal today. My direct view: hold off on buying today and wait for a cleaner entry.
DKNG is trading at 24.59, just above support at 24.081 and below the pivot at 25.02, which keeps the chart slightly bearish in the short term. MACD histogram is -0.0844 and negatively expanding, showing downside momentum. RSI_6 at 45.83 is neutral, so it is not oversold. Moving averages are converging, which suggests consolidation rather than a clear uptrend. Near-term pattern data also points to mixed performance, with downside probability dominating the next day and next week.
Analyst sentiment is still constructive overall, with multiple Buy/Overweight ratings and several raised price targets after Q1 results. Recent notes highlighted a Q1 beat, healthy sportsbook performance, fixed cost controls, and reiterated 2026 guidance. DraftKings is also viewed as having growth potential from prediction markets, which several analysts see as an important catalyst. News flow suggests management remains committed to investing in prediction-market platforms.
There is growing controversy around prediction markets, with regulators and 17 states disputing their structure and legality, which creates uncertainty around that growth path. BNP Paribas initiated coverage at Underperform with a $20 target, showing a more cautious Wall Street view. Insider selling is a major negative signal, with selling amount up sharply over the last month. Hedge funds are neutral, and there is no meaningful positive congressional trading data to support the stock.
Latest financial quarter: Q1. The available commentary says DraftKings delivered a small Q1 beat, healthier sportsbook performance, and stronger fixed cost control, while reaffirming its 2026 outlook. That points to improving operating discipline and steady growth trends, but the financial snapshot itself was unavailable, so the update is directionally positive rather than fully quantified.
Recent analyst trend remains mostly positive but more mixed than before. Several firms raised price targets or kept Buy/Overweight ratings, including Citi, Mizuho, Barclays, Wells Fargo, BTIG, and Guggenheim. Morgan Stanley slightly lowered its target but stayed Overweight. The main bearish outlier is BNP Paribas initiating Underperform at $20. Wall Street overall still leans bullish, but the pros now show a wider split on valuation and prediction-market risk. No recent politician or influential figure buying or selling was reported. No recent congress trading data was available.
